Peer Exchange

Biosimilars in Oncology: Addressing Awareness

Current State of Biosimilars: Approval, Availability, and Efficacy

Biosimilars in Oncology: Equivalency and Cost

Are Biosimilar Costs a Factor for Patients?

Biosimilars: Addressing Roadblocks to Market Adoption

Switching to Available Biosimilars in Oncology

Determining Biosimilars' Role in the Formulary

Market-Access Considerations for Biosimilars in Oncology

Where Do Biosimilars Fit in to the Treatment Landscape?

Multiple Biosimilars for a Single-Reference Biologic

Strategies for Incorporating Biosimilars Into Care Plans

Incorporating Biosimilars in Oncology: Working Collaboratively

Economic Impact of Biosimilars in Oncology

Biosimilars in Oncology: Long-Term Financial Benefit

Competition in the Biosimilar Marketplace

Biosimilars in Oncology: Future Directions

Pfizer's Citizen Petition on Biosimilar Communications

Combating Misinformation and Misconceptions About Biosimilars

Targeted Education for Biosimilar Stakeholders

US Versus EU Education on Biosimilars

The FDA's Approach to Biosimilar Education

Biosimilarity, Manufacturing Changes, and Comparability

Clinicians' Understanding of Manufacturing Changes

The Extrapolation of Indications

Selecting the Most Sensitive Population for Confirmatory Trials

Immunogenicity and Biosimilars

Misconceptions About Interchangeability

Clinical Studies for Biosimilars

The Future of US Biosimilars

The Role of Biosimilars in the US Healthcare System

Allowing the US Biosimilars Market to Flourish

Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use

Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars

Madelaine Feldman, MD: Practical Considerations for Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars

Patient Awareness of Biosimilars and Loyalty to Branded Drugs

Patient Savings From Biosimilars

Barriers to Biosimilars for Oncology Patients

Biosimilars, Payers, and Formulary Changes

The Exceptions Process and its Effect on Patients

Patient Education on Coverage for Biologics and Biosimilars

Alternative Payment Models and Patient Care

The Cost of Biologics and Biosimilars

Rebates and Medicare Part D

CMS' Changes to Reimbursement for Biosimilars

Biosimilars, Private Payers, and Pharmacy-Level Substitution

Patient Assistance Programs and Biosimilars

Manufacturers and the Cost of Biosimilars and Biologics

Diversity in Clinical Trials for Biosimilars

The FDA and Diversity in Clinical Trials

Oncology Biosimilars Making a Difference for Patients

Putting Patients at the Center of the Biosimilar Conversation

Biosimilar Interchangeability and Market Share

Interchangeability and Rheumatology Prescribing Practices

Biosimilars, Interchangeability, and Perceptions of Safety

Global Reference Products in Biosimilar Development

Inspection Reports and Proprietary Information

Reforms at the FDA Level

Biosimilars, Formularies, Contracting, and PBMs

Biosimilar Uptake and Health Plans

CMS and Blended Reimbursement Codes

Healthcare Reform Efforts and the BPCIA

State Laws and Biosimilar Substitution

The PTAB's Role in Biosimilar Patent Disputes

The Need for Clarity After <i>Sandoz v Amgen</i>

Upcoming Patent Litigation in Biosimilars

Challenges Ahead for Biosimilars

Adoption of Biosimilars in the United States and Europe

Delivery Systems and the Acceptance of Biosimilars

Cost and Biosimilar Uptake for Oncology

Biosimilar Prescribing and Cost in Rheumatology

Prescribing Behaviors and Biosimilar Substitution

Chronic Therapy and Switching

Physician Understanding of Biologic Manufacturing

Clinical Trial Design With Biosimilars

Post-Market Pharmacovigilance

Patient Awareness of Biosimilar Products

Payer Intervention and Biosimilar Switching

Extrapolation of Indications in Biosimilars

Cost and Biosimilars in Oncology

Competition and Cost for Biosimilars

Cost, Patient Programs, and Access to Biosimilars

Naming and Coding of Biosimilars

State Legislation on Biosimilars and Substitution

Biosimilars in the Next 5 Years

Knowledge Gaps With Biosimilars

Differences Between Biosimilars and Generic Drugs

Approval Process for Biosimilars

Naming of Biosimilars

Clinical Experience With Biosimilars

Use of Biosimilars in Inflammatory Diseases

Cost and Prescribing Considerations for Biosimilars

Variables Affecting Cost for Biosimilars

Formulary Considerations for Biosimilars

Challenges in Discussing Biosimilars With Patients

Clinician Awareness of Future Biosimilars

The Future of Biosimilars and Managing Inflammatory Diseases